Statistical analysis of biomarker data. Comparison of average cytokine levels across all CAR-T patients on days of CRS (ie, grade ≥1) vs days of no CRS (ie, grade 0) for IL-1β (Α), TNF-α (B), IL-10 (C), IL-6 (D), IL-12 (E), MCP-1 (F), INF-γ (G), IL-2 (H), IL-8 (I), IL-17A (J), CRP (K), and ferritin (L). Each error band indicates the mean with standard deviation. “Baseline” represents data from measurement time points before CAR T-cell infusion. Note that the data includes those obtained from the time points at which patients experiencing CRS were put on steroids or immunosuppressive agents (tocilizumab, infliximab), which could affect cytokine biomarker concentrations. (M) IL-6 variations over 4 different phases of tocilizumab treatment combined for 3 CAR-T patients who received the treatment. “on toci” represents 0 to 3 days after the tocilizumab administration, and “after toci” represents >3 days after the tocilizumab administration. Statistically significant elevations of IL-6 in serum were temporarily observed in the “on toci” phase (P < .01). *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, P ≥ .05.